C-817

N/A

Report date: 2022/07/01 15:29:28
NME

Base Information

Drug NameC-817
Drug Alias NameC-817
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionBcr-Abl tyrosine kinase inhibitors
TargetsBcr-Abl tyrosine kinase
Therapy Area/IndicationsLeukemia, Myelogenous, Chronic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesFujian Medical University
China Registration ClassN/A

Develop Information

Active CompaniesFujian Medical University
Inactive CompaniesN/A
Active IndicationsLeukemia, Myelogenous, Chronic
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A